Regorafenib Stivarga

What it is

Regorafenib is an oral multi-kinase inhibitor approved for treatment of metastatic colorectal cancer in patients who have progressed after standard therapies including fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and anti-EGFR therapy (if RAS wild-type). It serves as a third-line or later treatment option for refractory metastatic disease. The drug demonstrates activity across different molecular subtypes of CRC, including both microsatellite stable (MSS) and microsatellite instability-high (MSI-H) tumors.

How it works

Regorafenib inhibits multiple protein kinases involved in oncogenesis, angiogenesis, and maintenance of the tumor microenvironment, including VEGFR1-3, TIE2, PDGFR, FGFR, KIT, RET, and RAF kinases. By blocking these pathways simultaneously, it disrupts tumor cell proliferation, tumor angiogenesis, and metastasis. The multi-targeted approach helps overcome resistance mechanisms that develop against single-pathway inhibitors.

Molecular targets

Common side effects

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.